#ovariancancer search results
The Immunotherapy Era has officially arrived for Platinum-Resistant Ovarian Cancer! 📢 #FDA Approval (Feb 10, 2026): Pembrolizumab combination now approved based on KEYNOTE-B96. A huge step forward for PD-L1+ patients #OvarianCancer #Oncology #Immunotherapy #Keytruda
PYNNACLE phase II p53 reactivated against TP53 Y220Cm patients with platinum resistant #ovariancancer with ORR44% (1 radiographic CR). TP53 Y220C VAF decline seems to correlate to radiographic response! #SGOAM26 @SGO_org
Gain the knowledge and confidence to make optimal treatment decisions for your patients. This #CME focuses on the latest standards in advanced #OvarianCancer care, from management to patient-centered planning. ▶️ms.spr.ly/6014sIQtr
#FDA approval alert: Breaking Chemo-Resistance in #OvarianCancer The ROSELLA Trial! FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer 🔗 fda.gov/drugs/resource… #ROSELLATrial #PrecisionMedicine
Pembrolizumab + weekly paclitaxel ± bevacizumab in pts with platinum-resistant ovarian cancer led to improved PFS, OS in overall, PD-L1 CPS ≥ 1 populations #ovariancancer 🗣️From #ESMO25 👩⚕️Presenter Nicoletta Colombo, MD, PhD; Discussant @CoquardRay ascopost.com/news/november-…
Meta-analysis (@JAMANetworkOpen) revealed first-line PARPi maintenance after platinum chemo in advanced #ovariancancer improves PFS but no OS benefit, higher toxicity Experts urge personalized strategy 🔷Tibor A. Zwimpfer, MD 🔷Stamatios Petousis, PhD, MD ascopost.com/news/november-…
Featured: Effect of Diaphragmatic Resection Versus Stripping in Advanced #OvarianCancer : Impact on Patient Complications in a Large Retrospective Cohort Study at a Tertiary Referral Center rdcu.be/e1cAA @esragbilir @SyedAAhmad5 @SocSurgOnc
🚺 New signal in platinum-resistant #ovariancancer Investigational ADC QLS5132 showed: ☑️ 50% response rate ☑️ 94% disease control rate ☑️ Manageable safety 🗣️ Presented by Tao Zhu, MD of Zhejiang Cancer Hospital at #AACR26 🔗 ascopost.com/news/april-202…
The FDA just changed how we sequence Platinum Resistant #OvarianCancer . Yesterday’s approval of #Relacorilant (Lifyorli) + nab- #paclitaxel (March 25, 2026) moves us past "chemo-switching" and into Resistance-Modulating. The utility here is pure biology: we’re finally targeting
New SGO publications are now live in @gynoncjnls. Explore post-treatment surveillance shaping today’s clinical decisions, #PARPinhibitor approvals & updated guidance on NACT for #OvarianCancer: ow.ly/lfRM50Ycwnp
💆Cancer-related fatigue remains an unmet need in #ovariancancer. New evidence suggests self-acupressure is a safe, accessible option that can meaningfully reduce fatigue & improve quality of life in #cancersurvivors. 🔹Suzanna M. Zick, ND, MPH - @umichsph ascopost.com/news/february-…
No reliable screening test exists for #ovariancancer —but prevention may be possible. Emerging evidence shows opportunistic salpingectomy during routine abdominal surgery could prevent nearly 80% of ovarian cancers ❕ @JosephSakran, @KaraLongRoche ascopost.com/news/november-…
Among women worldwide, #OvarianCancer is the eighth most common malignancy and cause of cancer death. 📄 This JAMA Patient Page describes ovarian cancer and its risk factors, symptoms, diagnosis, and treatment. ja.ma/41eEKM7
The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO) Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer WATCH HERE👉 buff.ly/P3fusql In 2025, the standard 1L maintenance strategy in ovarian cancer remains unchanged:
📊 Final data from phase III AGO-OVAR 2.29: No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent #ovariancancer, though a paclitaxel subgroup showed a favorable OS signal. 🔸 Philipp Harter, MD | @JCO_ASCO 🔗 ascopost.com/news/january-2…
🔬 Targeting glucocorticoid signaling may enhance chemo response. In phase III ROSELLA trial: Relacorilant + nab-paclitaxel improved survival in platinum-resistant #ovariancancer (HR = 0.70). 🔸 Domenica Lorusso, MD | @TheLancet Explore the findings: ascopost.com/news/april-202…
#EditorsChoice Lymphadenectomy in early-stage #ovariancancer: is there still a role? @gcarusomd Lymphadenectomy decisions should be individualized by: 🔬Histotype 📶 Grade 📌 Stage 🧬 Biomarkers 💡 bit.ly/41YRyXg @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2
From 2018 to 2023, use of minimally invasive surgery (MIS) for stage I #OvarianCancer increased, but MIS was linked to higher intraoperative capsule rupture rates and lower overall survival when rupture occurred. ja.ma/4e0WIt5
Mutant p53 Selective Reactivation Demonstrated in Advanced Solid Tumors Team is focused on advancing rezatapopt as a potential first-in-class therapy for #ovariancancer patients harboring a TP53 Y220C mutation @pmvpharma #p53gene #clinicaltrials genengnews.com/topics/cancer/…
Take control of your ovarian health. Science is proving the power of cannabis in the fight against ovarian cancer. Read The Blog Here: f.mtr.cool/gmdjbpmrrm #OvarianCancer #CannabinoidResearch #OncologyNews
Published: Use of hyperthermic intraperitoneal chemotherapy ( #HIPEC ) in the treatment of #OvarianCancer : A multidisciplinary review ow.ly/NmS950YTan3 @FlavioRochaMD @DrMikeCavnar @SKMaithel @HalletJulie @JulietOkoroh @TheNotoriousHPB @AradhyaNigamMD @SocSurgOnc
Ovarian cancer is the 'silent killer,' yet our #NorthernIreland leaders remain silent One late diagnosis is one too many. We need urgent action, not political indifference. 🔇 #ovariancancer #cancerawareness @healthdpt @publichealthni @TargetOvarian 📢
On 5/3, I issued a FOI request👇to @healthdpt seeking info on basis of harmful decision of Minister to ban @publichealthni spending funds on media awareness campaigns year after year against view of PYA experts & his CMO Still waiting ⏰ Lots to hide?🤔 x.com/sja_mcc/status…
Just reading this good news brings me so much #Joy ❤️🫂 #cancerawareness #ovariancancer 🩵
May is Women’s Health Month. We are proud of our members and volunteers who work tirelessly to improve the health and quality of life of gynae cancer patients. Hats off to you this month and always! 🥳 #nowomanleftbehind #ovariancancer #gynonc
Take control of your ovarian health. Science is proving the power of cannabis in the fight against ovarian cancer. Read The Blog Here: f.mtr.cool/bulfdhdlcb #OvarianCancer #CannabinoidResearch #OncologyNews
💬 In an interview, Dr Alexander Olawaiye (@UPMCHillmanCC) discusses the impact of the #FDA approval of relacorilant plus nab-paclitaxel in platinum-resistant #OvarianCancer. #GynOnc Read the full interview: targetedonc.com/view/dr-olawai…
Up to 20% of ovarian cancer cases are tied to an inherited mutation. Yet most carriers don't know. Genetic testing isn't just about risk — it can change how you're treated, and protect your family. Here's what you need to know: nottheseovaries.org/germline-mutat… #OvarianCancer #WomensHealth
Did you know there’s no routine screening test for ovarian cancer? Knowing the symptoms is the first step towards early detection. Learn the signs and how you can support awareness: mckinleymc.com.au/blog/teal-ribb… #OvarianCancer #TealRibbon #HealthTips #MelbourneHealth #GPAdvice
Take control of your ovarian health. Science is proving the power of cannabis in the fight against ovarian cancer. Read The Blog Here: f.mtr.cool/fdmmkzcvkr #OvarianCancer #CannabinoidResearch #OncologyNews
My top 5 (in order) Know the symptoms Tell GP you’re worried about #ovariancancer & need action ASAP Keep going back to GP if symptoms don't improve, even if CA125 test results normal Keep a symptoms diary Irritable bowel syndrome has similar symptoms to #ovariancancer
After 16 years of #menopause , I’m ready to cut ties. Hot flashes, night sweats, brain fog, it’s just been too much. It’s not me, it’s you menopause. Time for you to move on! I’m going to be 40 this year & we just need to break up. #cancersurvivor #ovariancancer #cancer
Can avutometinib + defactinib deliver durable, long-term responses in recurrent low-grade serous ovarian cancer? Rachel N. Grisham, MD (@MSKCancerCenter) breaks down the ENGOT-ov60/GTG-UK/GOG-3052 data. hubs.li/Q04dX3WW0 #OvarianCancer #LGSOC #Oncology #GynOncology
If you think you might have the #symptoms of #ovariancancer, it's important to see your GP. We know that first conversation can be difficult, so we worked with @macmillancancer on top tips to help you talk to your GP. See our top 10 tips 👉 bit.ly/3LHZqT5
Bradley Monk, MD, on the pivotal role of biomarker testing in recurrent ovarian cancer. A new OncLive TV episode is coming soon. Explore more biomarker content: hubs.li/Q04dWCy00 #OvarianCancer #RecurrentOvarianCancer #BiomarkerTesting #OncLiveTV #GynecologicOncology
Still thinking about the magic from last year’s Boston Building Hope event! ✨ We’re so excited to bring our Boston community back together Tues, May 19 (6–9 PM) at @AFHBoston. All proceeds support early detection & prevention of #OvarianCancer. tinaswish.org/boston26/
Ovarian cancer cases are rising among younger adults in England, with bowel cancer showing a similar pattern, a study suggests. 🔗 Full story: buff.ly/isBnyzJ #OvarianCancer #CancerResearch #WomensHealth #PublicHealth #HealthTrends
Cleo Diagnostics Quarterly Activities Report March 2026. Link to release: bit.ly/MarchQuarter #CleoDX #ovariancancer #ovarian #cancer #medtech #womenshealth #invest ASX.COV
Concurrent Appendectomy in Patients Undergoing Surgery for Gynecological Malignancies: A Retrospective Analysis from a Tertiary Referral Center #metastasispathology #appendectomy #ovariancancer smj.researchcommons.org/cgi/viewconten…
PYNNACLE phase II p53 reactivated against TP53 Y220Cm patients with platinum resistant #ovariancancer with ORR44% (1 radiographic CR). TP53 Y220C VAF decline seems to correlate to radiographic response! #SGOAM26 @SGO_org
💬 Viewpoint: #OvarianCancer's unique attributes complicate early detection, necessitating personalized risk-based strategies for better prevention and outcomes. ja.ma/3Jwfzzu
Meta-analysis (@JAMANetworkOpen) revealed first-line PARPi maintenance after platinum chemo in advanced #ovariancancer improves PFS but no OS benefit, higher toxicity Experts urge personalized strategy 🔷Tibor A. Zwimpfer, MD 🔷Stamatios Petousis, PhD, MD ascopost.com/news/november-…
🧬 Platinum resistance isn't the end — it's the beginning of new strategies. A selective glucocorticoid receptor antagonist #relacorilant shows promise in shifting the standard for platinum-resistant #ovariancancer ⚙️ Cortisol blockade = chemo re-sensitization Precision
Can avutometinib + defactinib deliver durable, long-term responses in recurrent low-grade serous ovarian cancer? Rachel N. Grisham, MD (@MSKCancerCenter) breaks down the ENGOT-ov60/GTG-UK/GOG-3052 data. hubs.li/Q04dX3WW0 #OvarianCancer #LGSOC #Oncology #GynOncology
The Immunotherapy Era has officially arrived for Platinum-Resistant Ovarian Cancer! 📢 #FDA Approval (Feb 10, 2026): Pembrolizumab combination now approved based on KEYNOTE-B96. A huge step forward for PD-L1+ patients #OvarianCancer #Oncology #Immunotherapy #Keytruda
4th and final Practice-relevant win presidential for today by #NicolettaColombo. ENGOT-ov65/KEYNOTE-B96: pembro + weekly paclitaxel +/- bev improves PFS (8.3 vs 6.4 mo; HR 0.70) in platinum-resistant ovarian cancer and OS benefit in PD-L1 CPS≥1 (HR 0.76). #ESMO25 #OvarianCancer
New multicenter study assesses germline variants in patients with epithelial #OvarianCancer from North China using multigene panel analysis to evaluate their prevalence, clinical significance, and prognostic impact. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… @OncoAlert #gyncsm
Pembrolizumab + weekly paclitaxel ± bevacizumab in pts with platinum-resistant ovarian cancer led to improved PFS, OS in overall, PD-L1 CPS ≥ 1 populations #ovariancancer 🗣️From #ESMO25 👩⚕️Presenter Nicoletta Colombo, MD, PhD; Discussant @CoquardRay ascopost.com/news/november-…
This new editorial by Drs. Susana Campos, Jessica DiSilvestro, and Stephanie Blank comments on results of the FZOCUS-1 trial testing fuzuloparib & apatinib as maintenance treatment after 1st-line therapy in #OvarianCancer. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert #GYNCSM
💬 In an interview, Erin Crane, MD, MPH (@AtriumHealth) explores how HRD and BRCA results steer frontline #OvarianCancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency. hubs.li/Q043BlHJ0
Among women worldwide, #OvarianCancer is the eighth most common malignancy and cause of cancer death. This JAMA Patient Page describes ovarian cancer and its risk factors, symptoms, diagnosis, and treatment. ja.ma/3KlMkzJ
Featured: Effect of Diaphragmatic Resection Versus Stripping in Advanced #OvarianCancer : Impact on Patient Complications in a Large Retrospective Cohort Study at a Tertiary Referral Center rdcu.be/e1cAA @esragbilir @SyedAAhmad5 @SocSurgOnc
This new #OpenAccess study highlights that KT127 has a manageable safety profile and shows preliminary biological activity in patients with advanced #OvarianCancer, particularly those who have failed multiple lines of therapies. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… @OncoAlert #gyncsm
Gain the knowledge and confidence to make optimal treatment decisions for your patients. This #CME focuses on the latest standards in advanced #OvarianCancer care, from management to patient-centered planning. ▶️ms.spr.ly/6014sIQtr
No reliable screening test exists for #ovariancancer —but prevention may be possible. Emerging evidence shows opportunistic salpingectomy during routine abdominal surgery could prevent nearly 80% of ovarian cancers ❕ @JosephSakran, @KaraLongRoche ascopost.com/news/november-…
From 2018 to 2023, use of minimally invasive surgery (MIS) for stage I #OvarianCancer increased, but MIS was linked to higher intraoperative capsule rupture rates and lower overall survival when rupture occurred. ja.ma/4e0WIt5
🚺 New signal in platinum-resistant #ovariancancer Investigational ADC QLS5132 showed: ☑️ 50% response rate ☑️ 94% disease control rate ☑️ Manageable safety 🗣️ Presented by Tao Zhu, MD of Zhejiang Cancer Hospital at #AACR26 🔗 ascopost.com/news/april-202…
The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO) Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer WATCH HERE👉 buff.ly/P3fusql In 2025, the standard 1L maintenance strategy in ovarian cancer remains unchanged:
Something went wrong.
Something went wrong.
United States Trends
- 1. #SmackDown N/A
- 2. RJ Barrett N/A
- 3. Magic N/A
- 4. Toronto N/A
- 5. Cavs N/A
- 6. Pistons N/A
- 7. McAvoy N/A
- 8. Game 7 N/A
- 9. #LetsGoBuffalo N/A
- 10. Mobley N/A
- 11. #OPLive N/A
- 12. #GoBolts N/A
- 13. #LetEmKnow N/A
- 14. Donovan Mitchell N/A
- 15. Benson N/A
- 16. Scottie Barnes N/A
- 17. Sami N/A
- 18. James Harden N/A
- 19. Kenny Atkinson N/A
- 20. Gingerbread Man N/A